DuoResp Spiromax® is a new intuitive dosing dry powder inhaler of budesonide and formoterol
https://doi.org/10.18093/0869-0189-2016-26-4-498-504
Abstract
A review of efficacy of budesonide/formoterol fixed combination in obstructive lung diseases has been done in the article. The efficacy of this combination in chronic obstructive pulmonary disease (COPD) and asthma has been supported by high-level evidence. Clinical effect of inhalation therapy depends on proper use of the inhaler. Information on a new dosing dry powder inhaler DuoResp Spiromax® is given in the review. The ease of use of this inhaler is close to intuitive use. According to comparative trials, DuoResp Spiromax® is a promising inhaler which could improve the therapeutic efficacy and reduce cost of treatment of COPD and asthma.
About the Authors
A. A. Vizel'
Kazan State Medical University, Healthcare Ministry of Russia: 49, Butlerova str., Kazan', 420012, Tatarstan Republic
Russian Federation
Russian Federation
MD, Professor, Head of Department of Phthisiology and Pulmonology, Kazan State Medical University, Healthcare Ministry of Russia; tel.: (9872) 96-25-99;
I. Yu. Vizel'
Kazan State Medical University, Healthcare Ministry of Russia: 49, Butlerova str., Kazan', 420012, Tatarstan Republic
Russian Federation
Russian Federation
PhD, Assistant Lecturer at the Department of Phthisiology and Pulmonology, Kazan State Medical University, Healthcare Ministry of Russia; tel.: (9872) 96-25-99;
References
1. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9: 963–974.
2. Adeloye D., Chua S., Lee C. et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J. Glob. Health. 2015; 5 (2): 020415.
3. Braido F., Brusselle G., Guastalla D. et al. Determinants and impact of suboptimal asthma control in Europe: The international cross-sectional and longitudinal assessment on asthma control (LIAISON) study. Respir. Res. 2016; 17 (1): 51.
4. Global initiative for asthma (GINA). A pocket guide for health professionals: Updated 2016.
5. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD): Updated 2016.
6. Baker J.G. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br. J. Pharmacol. 2010; 160 (5): 1048–1061.
7. Willey R.F., Godden D.J., Carmichael J. et al. Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma. Br. J. Dis. Chest. 1982; 76 (1): 61–68.
8. Lähelmä S., Sairanen U., Haikarainen J. et al. Equivalent lung dose and systemic exposure of budesonide/formoterol combination via Easyhaler and Turbuhaler. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (6): 462–473.
9. Latorre M., Novelli F., Vagaggini B. et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS) / long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Pulm. Pharmacol. Ther. 2015; 30: 44–50.
10. Hozawa S., Terada M., Haruta Y., Hozawa M. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy. Pulm. Pharmacol. Ther. 2016; 37: 15–23.
11. Kew K.M., Karner C., Mindus S.M., Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2013; 12: CD009019.
12. Ekberg-Jansson A., Svenningsson I., Rågdell P. et al. Budesonide inhaler device switch patterns in an asthma population in Swedish clinical practice (ASSURE). Int. J. Clin. Pract. 2015; 69 (10): 1171–1178.
13. Scichilone N., Benfante A., Bocchino M. et al. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases? Pulm. Pharmacol. Ther. 2015; 31: 63–67.
14. Cohen J.S., Miles M.C., Donohue J.F., Ohar J.A. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Int. J. Chron. Obstruct. Pulm. Dis. 2016; 11: 785–797.
15. Laube B.L., Janssens H.M., de Jongh F.H.C. et al. What the pulmonary specialist should know about the new inhalation therapies: ERS/ISAM task force report. Eur. Respir. J. 2011; 37 (6): 1308–1331.
16. Wilson D.S., Gillion M.S., Rees P.J. Use of dry powder inhalers in COPD. Int. J. Clin. Pract. 2007; 61 (12): 2005–2008.
17. Wieshammer S., Dreyhaupt J. Dry powder inhalers: Which factors determine the frequency of handling errors? Respiration. 2008; 75:1 8–25.
18. Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011; 105 (6): 930–938.
19. Basheti I.A., Obeidat N.M., Ammari W.G., Reddel H.K. Associations between inhaler technique and asthma control among asthma patients using pressurised MDIs and DPIs. Int. J. Tuberc. Lung Dis. 2016; 20 (5): 689–695.
20. Kondo T., Tanigaki T., Hibino M. et al. Resistances of dry powder inhalers and training whistles and their clinical significance. Arerugi. 2014; 63 (10): 1325–1329.
21. Wolthers O.D., Shah T.A Comparison of short-term growth during treatment with two dry powder combinations of inhaled corticosteroids and long-acting β₂-agonists. J. Aerosol Med. Pulm. Drug Deliv. 2015; 28 (3): 182–188.
22. Canonica G.W., Arp J., Keegstra J.R., Chrystyn H. Spiromax, a new dry powder inhaler: dose consistency under simulated real-world conditions. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (5): 309–319.
23. Virchow J.C., Rodriguez-Roisin R., Papi A. et al. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax® compared to budesonide-formoterol TurbuhalerR in adults and adolescents with persistent asthma. BMC Pulm. Med. 2016; 16: 42.
24. Azouz W., Chetcuti P., Hosker H. et al. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax#R and Turbuhaler® devices: a randomised, cross-over study. BMC Pulm. Med. 2015; 15: 47.
25. Plusa T. Pijos P. Features of the ideal inhaler in testing a new inhaler devices. Int. Rev, Allergol. Clin. Immunol. Familiy Med., 2015; 21 (1): 21–24.
26. Sandler N., Holländer J., Långström D. et al. Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler). Br. Med. J. Open Respir. Res. 2016; 3 (1): e000119.
27. Chrystyn H., Safioti G., Keegstra J.R., Gopalan G. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler. Int. J. Pharm. 2015; 491 (1–2): 268–276.
28. Torvinen S., Nicolai J., Pulimeno S. et al. The budget impact of Duoresp® Spiromax® compared with commonly prescribed dry powder inhalers for the management of asthma and chronic obstructive pulmonary disease in Italy: estimated impact of inhalation technique. Value Health. 2015; 18 (7): A496.
Review
For citations:
Vizel' A.A., Vizel' I.Yu. DuoResp Spiromax® is a new intuitive dosing dry powder inhaler of budesonide and formoterol. PULMONOLOGIYA. 2016;26(4):498-504. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-4-498-504
Views:
1895
Email this article 